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Abstract: Background: Smoking is considered the most important preventable risk factor 
in relation to the development of complications during pregnancy and delivery. The aim of 
this study was to evaluate the effectiveness of an intensive 6-week gold standard 
programme (GSP) on pregnant women in real life. Methods: This was a prospective cohort 
study based on data from a national Danish registry on smoking cessation interventions. 
The study population included 10,682 women of a fertile age. The pregnancy status of the 
study population was identified using the National Patient Registry. Results: The response 
rate to follow up was 76%. The continuous abstinence rate for both pregnant and non-
pregnant smokers was 24–32%. The following prognostic factors for continuous abstinence 
were identified: programme format (individual/group), older age, heavy smoking, 
compliance with the programme, health professional recommendation, and being a 
disadvantaged smoker. Conclusions: The GSP seems to be as effective among pregnant 
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smokers as among non-pregnant smoking women. Due to the relatively high effect and 
clinical significance, the GSP would be an attractive element in smoking cessation 
intervention among pregnant women. 
Keywords: smoking cessation intervention; pregnancy; pregnant smokers; intensive 
programme; Gold Standard Programme (GSP); effectiveness; abstinence; prospective 
cohort study; national database; Denmark 
 
1. Introduction 
Worldwide, tobacco smoking is considered to be the second most important risk factor for global 
disease burden, surpassed only by high blood pressure [1]. In Western Europe, smoking is considered 
to be the most important risk factor for disease [1]. The severity of smoking is also highly relevant in 
the case of pregnancy, and in many countries, smoking is considered the most important preventable 
risk factor in relation to the development of complications during pregnancy and delivery [2].  
Many studies have established an increased risk of a number of serious complications associated 
with smoking during pregnancy that can affect both mother and child. These include spontaneous 
abortion, ectopic pregnancies, perinatal mortality, placental abruption, reduced prenatal development 
of lung function, preterm birth, low birth weight, conjugate malformations, growth reduction, 
hospitalisation within the first year of life, and sudden infant death syndrome [2–11]. Furthermore, a 
relationship between smoking during pregnancy and the development of behavioural disturbances and 
lifestyle problems in the child have been shown [2,4,12]. 
In 2005, the prevalence of women smoking at some point during their pregnancy was 16% on 
average in Denmark [13], which had decreased from 22% in 1997. From 1997 to 2005 there was a 
markedly higher smoking prevalence for pregnant women under the age of 25 years [13].  
Smoking among pregnant women is an issue focused on in the health care sector, and pregnant 
women are expected to have a higher motivation to quit smoking compared to other groups of 
smokers. In contrast, other general life conditions may reduce successful quitting, such as being 
unemployed, having no or very limited education, and being a heavy smoker [14,15], which can all be 
the case in pregnant women. 
Based on this knowledge, it is very important to evaluate how this specific group of smokers can 
obtain the best help to stop smoking during their pregnancy. This would be of high health importance 
to the pregnant woman and her child and would be beneficial for the society at large [3]. 
The aim of this study was to evaluate the effectiveness of intensive smoking cessation interventions 
(The Gold Standard Programme, GSP) on pregnant women in real life, meaning that the interventions 
had already been implemented into a normal routine in the smoking cessation clinics. The main 
hypothesis was that pregnant women undergoing the GSP would be more likely to be smoke-free after 
6 months compared to non-pregnant women of the same age. Furthermore, we wanted to identify 
factors associated with continuous abstinence. 
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2. Methods 
2.1. Study Design 
This study is a prospective cohort study based on data from a national Danish registry (Smoking 
Cessation Database, SCDB). The SCDB contains data from more than 79,000 smokers who have 
received face-to-face aid for quitting smoking. Of the face-to-face interventions in Denmark, 80–90% 
are registered in the SCDB, which is considered to be a representative sample [16]. This project was 
approved by the Danish Data Protection Agency (2010-41-5463/2000-54-0013) and registered with the 
Scientific Ethical Committee (H-C-FSP-2010-049). Based on data from the SCDB, we have recently 
published four papers [16–19]. 
2.2. Setting 
In the study period from 2006–2012, all smokers, including pregnant women, in Denmark had 
access to more than 230 smoking cessation clinics at different settings, such as hospitals, midwives, 
municipal clinics, pharmacies, primary care facilities, and other private institutions, that report data to 
the SCDB. All smokers in Denmark have access to SCIs without referral and free of charge. Less than 
5% of this study population chose to participate in a course where they had to pay. 
2.3. Intervention 
Since 2001, the GSP has been the standard smoking cessation intervention (SCI) in Denmark.  
It comprises 5–6 meetings during six weeks (in a group or as an individual intervention). The 
programme was based on counselling and a clearly structured manual-based patient education 
programme taught by specially trained staff [18–22]. The topics of the teaching sessions included 
ambivalence and motivation, pros and cons of continuous smoking versus cessation, setting a quit date, 
risk situations, withdrawal symptoms and medical support for withdrawal symptoms, relapse 
prevention and how to handle a completely smoke-free life. Furthermore, the programme contained 
individual counselling on nicotine replacement therapy (NRT) or other medical support, according to 
the level of dependence measured by the Fagerström test score [23]. Finally, a hotline was available 
during daytime hours on working days. The allocation of a single patient to the group or individual 
programme was at the discretion of the smoking cessation clinics or the instructors. Patients that 
attended at least 75% of the scheduled meetings were considered to be compliant with the programme 
as defined by the Steering Committee [17].  
2.4. Participants 
From 2006–2012, 27,139 women were registered in the SCDB after giving informed consent. Each 
woman was registered with a unique 10 digit personal identification number (PIN). The PIN was used 
to control for double entries, women attending more than 1 intervention, and for identifying pregnant 
women using data from The National Patient Registry. 
Women who were registered in the SCDB at a fertile age (between 15–54 years) and were 
participating in the GSP in Denmark were included in this study. The fertile age of 15–54 years was 
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determined by finding the youngest and the oldest pregnant smoker registered in the SCDB. The 
following women were excluded from this study: doublets or entries referring to women attending 
more than 1 SCI (n = 2,144); women younger than 15 years (n = 38) or older than 54 (n = 8.599); 
women attending interventions other than the GSP (n = 1,736); women not wanting to be contacted 
after 6 months (n = 404); and women who were intentionally not followed up with after 6 months  
(n = 3,536) because the smoking cessation clinic they attended pre-decided not to spend time to follow 
up on any of their patients. 
Thus, 10,682 women attending a GSP between 2006–2012 in Denmark were included in the study 
(see Figure 1). Pregnancy (including births, abortions, miscarriages and stillbirths) was identified 
according to the following ICD-10 codes; FB6601, FB6602, DO00-99, DZ321-DZ39, BKHD4-5, 
BKKG, BKXG, DN96, DN969, DZ098A, KLCH, KLWW00 and DP95. 
Figure 1. Patient flow. Distribution of women included in the study population according 
to the follow-up response and pregnancy status. Women 15–54 years of age that were 
attending the GSP in Denmark between 2006–2012 and attending follow up were included 
in this study. The non-responders included 2,547 (23.8%) women that were lost to follow up. 
 
2.5. Data 
Data from SCDB were sought by computer linkage in The National Patient Registry using the 10 
digit PINs. Women initiating a SCI from 4 months prior to a registered pregnancy in The National 
Patient Registry to 12 months after were eligible for inclusion in this study. This time period was 
chosen to ensure that the SCI was related to a pregnancy. If a woman was registered with more than 1 
SCI during the same pregnancy, the most recent one was included in the study. Likewise, if a woman 
was registered with more than 1 pregnancy, the most recent pregnancy was included. 
For all pregnant women with a matching GSP in the SCDB, the following relevant dates were 
registered; first contact, abortion/miscarriage, birth, stillbirth and/or contact after birth. In total, 9.4% 
of the responders and 9.3% of the non-responders were pregnant. 
2.6. Outcomes 
The primary outcome was self-reported continuous abstinence for six months, which was defined as 
not smoking at all from the intended quit date to the six month follow up. The smoking status was 
obtained by asking whether the patient had been continuously abstinent since the intended quit date 
reported to the SCDB. If an intended quit date was not reported, the last treatment date was used. The 
follow up was conducted as a telephone interview after 6 months ± 1 month. After four failed attempts 
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to reach the patient (at least one attempt had to be in the evening), the patient was reported as a non-
responder. 
Secondary outcomes were abstinence at the end of the programme (self-reported by the patient and 
observed by the SC counsellor), 14 days point prevalence assessed at the six month follow up by 
asking the patients if they have been abstinent for the latest 14 days, and patient satisfaction, also 
assessed at the six month follow up, determined by asking the patients (on a scale from 1–5) how 
satisfied they were with the course as a whole. 
2.6.1. Other Variables 
For each patient registered in the SCDB, data were collected on socio-demographic parameters, 
smoking history, their intervention programme and follow-up information. Age and smoking 
information were collected as continuous variables. The remaining variables were collected 
categorically and grouped as shown in Table 1.  
Table 1. Characteristics of pregnant and non-pregnant women. 
Women in GSP Pregnant  Non-pregnant 
    
 Characteristics 
n (%) 
 Characteristics  
n (%) 
All 1,006 (100)  9,676 (100) 
Setting      
 Midwife/Hospital 438 (43.5)  622 (6.4) 
 Other 568 (56.5)  9,054 (93.6) 
Programme format      
 Individual 240 (23.9)  994 (10.3) 
 Group 766 (76.1)  8,682 (89.7) 
Medication for free      
 No free medication 511 (50.8)  5,296 (54.7) 
 Free for <1 week 472 (46.9)  4,014 (41.5) 
 Free for <5 weeks 3 (0.3)  75 (0.8) 
 Free for ≥5 weeks 17 (1.7)  279 (2.9) 
 Free for unknown period of time 3 (0.3)  12 (0.1) 
Age (years)      
 15–24 240 (23.9)  704 (7.3) 
 25–34 549 (54.6)  1,522 (15.7) 
 35–44 213 (21.2)  3,083 (31.9) 
 45–54 4 (0.4)  4,367 (45.1) 
Smoking      
 <20 pack-years 885 (88.0)  4,549 (47.0) 
 ≥20 pack-years 121 (12.0)  5,127 (53.0) 
 Fagerström 1–4 points 451 (44.8)  3,658 (37.8) 
 Fagerström 5–10 points 555 (55.2)  6,018 (62.2) 
 <20 cigarettes per day 691 (68.7)  4,739 (49.0) 
 ≥20 cigarettes per day 315 (31.3)  4,937 (51.0) 
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Table 1. Cont. 
Women in GSP Pregnant  Non-pregnant 
    
 Characteristics 
n (%) 
 Characteristics  
n (%) 
Heavy smokers a      
 Yes 370 (36.8)  6,350 (65.6) 
 No 636 (63.2)  3,326 (34.4) 
Compliance with programme b      
 Compliant 476 (47.3)  5,377 (55.6) 
 Not compliant 507 (50.4)  4,121 (42.6) 
 Unknown 23 (2.3)  178 (1.8) 
Living with a smoker      
 Yes 523 (52.0)  3,615 (37.4) 
 No 479 (47.6)  5,981 (61.8) 
 Unknown 4 (0.4)  80 (0.8) 
Attempts to quit      
 No previous attempts 421 (41.8)  3,616 (37.4) 
 Previous attempts 573 (57.9)  5,896 (60.9) 
 Unknown 12 (1.2)  176 (1.8) 
Professional recommendation      
 Yes from midwife or medical doctor 711 (70.7)  3,995 (41.3) 
 Yes from others 42 (4.2)  977 (10.1) 
 No 213 (21.2)  4,265 (44.1) 
 Unknown 40 (4.0)  239 (2.5) 
Education      
 Low level 364 (36.2)  2,515 (26.0) 
 Medium level 255 (25.3)  2,552 (26.4) 
 High level 372 (37.0)  4,324 (44.7) 
 Unknown 15 (1.5)  285 (2.9) 
Employment      
 Employed 578 (57.5)  6,900 (71.3) 
 Unemployed 277 (27.5)  1,771 (18.3) 
 Enrolled in education 132 (13.1)  671 (6.9) 
 Unknown 19 (1.9)  334 (3.5) 
Disadvantaged smokers c      
 Yes 493 (49.0)  3,541 (35.6) 
 No 495 (49.2)  5,757 (59.5) 
 Unknown 18 (1.8)  378 (3.9) 
a Heavy smokers: smoking ≥20 pack-year and/or daily consumption of ≥20 cigarettes and/or 
Fagerström nicotine dependency score of ≥7 point [19,23]; b Compliance with the programme was 
defined as having attended at least 75% of the scheduled meetings [17]; c Disadvantaged smokers: 
unemployed and receiving unemployment benefits and/or low education (no education except 
elementary school (≥12 years) or only short work-related courses) [18]. 
Compliance with the programme was defined as having attended at least 75% of the scheduled 
meetings [17]. 
Int. J. Environ. Res. Public Health 2013, 10 3659 
 
 
Heavy smokers were defined as patients fulfilling at least one of the following three criteria: 
smoked at least 20 pack-years, had a daily consumption of 20 cigarettes or more, or had a nicotine 
dependency of 7 points or more as measured on the Fagerström score [19,23]. 
Disadvantaged smokers were defined as patients fulfilling at least one of the following two criteria: 
were unemployed and receiving unemployment benefits, or had a low education level, meaning no 
education except elementary school (up to 12 years) or only short work-related courses [18]. 
2.6.2. Sub-Analyses 
The following sub-analyses were conducted to establish if there was a difference in the continuous 
abstinence rates: pregnant women who gave birth to a living child compared to women that had a 
miscarriage, pregnant women who miscarried compared to non-pregnant women of the same age, 
older pregnant women (≥25 years) compared to younger pregnant women (<25 years), pregnant 
disadvantaged smokers compared to non-pregnant disadvantaged smokers of the same age and 
pregnant heavy smokers compared to non-pregnant heavy smokers of the same age. Finally, a  
sub-analysis was performed to evaluate the compliance with the programme for non-pregnant women 
compared to pregnant women. 
2.7. Statistical Analysis 
The data were analysed and reported according to the STROBE recommendations [24]. This 
included reporting missing data, loss of follow up data and the analyses of the non-responders. 
Randomised studies usually report the effect of an intervention according to the Russell Standards [25], 
which assume that non-responders have relapsed. To be able to compare this study to efficacy 
research, we also reported the continuous abstinence according to these criteria.  
Univariate and multivariate logistic regression analyses were used to test for differences in 
continuous abstinence. The logistic analyses were adjusted for all of the prognostic factors shown in 
Table 2. Statistically significant predictors of continuous abstinence were compared by calculating the 
odds ratio (OR) and the corresponding 95% confidence intervals (CI). Logistic regression analyses 
were performed by entering all the predictors together. The patients with ‘unknown’ values were 
excluded from the analyses. These numbers were considered small and acceptable for a real life study. 
The analyses were repeated for each of the secondary outcomes. 
Sub-analyses were performed using the Mantel-Haenszel test for stratified 2×2 tables. A non-responder 
analysis was performed by comparing the characteristics of responders and non-responders. A two-sided 
p value of <0.05 was regarded as significant. All statistical calculations were performed with StataSE 12. 
3. Results 
The characteristics of the study population showed that non-pregnant and pregnant smokers were 
different with regard to the following: setting of GSP, programme format (individual/group), age, 
being a heavy smoker, compliance, living with a smoker, professional recommendation, and being a 
disadvantaged smoker (education and employment) (see Table 1). 
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Our study showed that the continuous abstinence rate was not different in pregnant women  
(24.5–32.0%) compared to non-pregnant women (24.1–31.7%). The following several factors were 
shown to be important for the abstinence rate: programme format, young age, not being compliant with 
the programme, being recommended to stop by professionals, being a disadvantaged smoker (without 
work and/or short-cycle or no education) and being a heavy smoker (see Table 2). 
Table 2. Primary outcome: ORs with 95% CI for continuous abstinence rates after 6 
months for the prognostic factors of the univariate (non-adjusted) and the adjusted 
multivariable analyses are presented. 
Women in GSP  
 Non-adjusted ORs 
(95% CI) 
Adjusted ORs  
(95% CI) 
Pregnancy   
 Non-pregnant 1  
 Pregnant 1.02 (0.87–1.21) 1.16 (0.95–1.42) 
Setting   
 Midwife/Hospital 1  
 Other 0.94 (0.79–1.12) 0.96 (0.79–1.17) 
Programme format   
 Individual 1  
 Group 0.72 (0.62–0.84) 0.79 (0.67–0.93) * 
Medication for free   
 No free medication 1  
 Free for <1 week 0.87 (0.78–0.96) 0.93 (0.83–1.04) 
 Free for <5 weeks 1.17 (0.69–2.02) 1.07 (0.61–1.88) 
 Free for ≥5 weeks 1.31 (0.98–1.75) 1.22 (0.89–1.66) 
Age (years)   
 25–54 1  
 15–24 0.56 (0.46–0.70) 0.65 (0.51–0.82) * 
Heavy smokers a   
 Yes 1  
 No 1.50 (1.35–1.66) 1.42 (1.27–1.58) *  
Compliance with programme b   
 Compliant 1  
 Not compliant 0.27 (0.24–0.31) 0.29 (0.26–0.32) * 
Living with a smoker   
 Yes 1  
 No 1.16 (1.05–1.29) 1.11 (1.00–1.24) 
Attempts to quit   
 No previous attempts 1  
 Previous attempts 1.13 (1.02–1.25) 1.03 (0.92–1.15) 
Professional recommendation   
 Yes from midwife or medical doctor 1  
 Yes from others 1.24 (1.04–1.47) 1.19 (0.99–1.43) 
 No 1.25 (1.13–1.40) 1.18 (1.06–1.33) * 
Disadvantaged smokers c   
 Yes 1  
 No 1.33 (1.19–1.47) 1.16 (1.04–1.30) * 
a Heavy smokers: smoking ≥20 pack-year and/or daily consumption of ≥20 cigarettes and/or Fagerström nicotine 
dependency score of ≥7 point [19,23]; b Compliance with the programme was defined as having attended at least 75% of 
the scheduled meetings [17]; c Disadvantaged smokers: unemployed and receiving unemployment benefits and/or low 
education (no education except elementary school (≥12 years) or only short work-related courses) [18]. * Significant. The 
results were considered significant if the 95% CI did not include the value 1. 
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3.1. Secondary Outcomes 
The 14 days point prevalence for being smoke-free after 6 months showed a significant difference 
between pregnant and non-pregnant women (1.27; 1.05–1.54). No difference was shown between 
pregnant and non-pregnant women in regard to being smoke-free at the end of the programme or in the 
satisfaction with the programme (see Table 3). 
Table 3. Secondary outcomes: Abstinence at the end of the programme, 14 days point 
prevalence and satisfaction with the programme for pregnant and non-pregnant women 
(given as the % of all pregnant or non-pregnant patients and responders only). The OR and 
95% CI are shown. 
Women in GSP Pregnant    Non-pregnant   
  Effect (%)   Effect (%) 
 Characteristics (n) All Responders  Characteristics 
(n) 
All Responders 
Patients   1,006 735   9,676 7,252 
 Smoke free at end of programme 419 41.7% 57.0%  4,729 48.9% 65.2% 
 OR (95% CI) 0.98 (0.78–1.21)    1   
Patients   1,006 763   9,676 7,319 
 Point prevalence (14 days) 306 30.4% 40.1%  2,801 28.9% 38.3% 
 OR (95% CI) 1.27 (1.05–1.54) *    1   
Patients   1,006 742   9,676 7,170 
 Satisfied with the programme 600 59.6% 80.9%  5,853 60.5% 81.6% 
 OR (95% CI) 1.00 (0.79–1.26)    1   
* Significant. The results were considered significant if the CI did not include the value 1. 
3.2. Sub-Analyses 
Furthermore, several sub-analyses were performed. The analysis of disadvantaged pregnant women 
compared to disadvantage non-pregnant women showed a significantly better continuous abstinence 
rate for younger pregnant disadvantaged women (2.19; 1.29–3.66). The same effect was not observed 
for older disadvantaged smokers (0.78; 0.57–1.08). Finally, non-pregnant women were more compliant 
to the programme compared to pregnant women (1.39; 1.22–1.59). 
3.3. Non-Responder Analysis 
The proportion of non-responders was 23.8%. The characteristics shown in Table 1 were included 
in a non-responder analysis. The analysis showed that non-responders were significantly more likely to 
be non-compliant (p < 0.001), to be younger (p < 0.001), to be disadvantaged (p < 0.001) and to have 
had a SCI in a setting other than a midwife/hospital (p < 0.001). 
4. Discussion 
Our study showed that there was a similar effect of the gold standard programme (GSP) on 
pregnant and non-pregnant women in this large study investigating real life data. Successfully quitting 
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smoking was associated with the individual counselling format, older age, higher compliance, not 
being a heavy smoker and not having disadvantaged life conditions. When sub-analysing the group of 
disadvantaged smokers, the programme had a higher effect on the young pregnant women than the 
young non-pregnant women, while this was not the case in the older group of disadvantaged smokers. 
Because all smokers in Denmark have access to SCIs without referral and free of charge, we consider 
the selection bias to be limited. 
The abstinence rate in our study was relatively high compared to other studies on pregnant women. 
During late pregnancy, the rate of smoking cessation has been reported to be 13% (ranging from  
7–23%) in a recent review of efficacy and safety of pharmacotherapy for smoking cessation among 
pregnant smokers [26]. Studies on follow-up from intervention in real life settings have shown similar 
results [27]. The results in the current study showed a quit rate of 24.5% to 32.2% in pregnant smokers 
and 24.1% to 31.8% in non-pregnant smokers. From 1997 to 2005 an average of 13.4% of the pregnant 
smokers in Denmark stopped smoking [13]. Compared to these numbers, the effect of the GSP is very 
high and seems to be an effective intervention for pregnant smokers. Other studies on the GSP have 
shown a similar high effect in real life [16–19].  
We had expected to find that pregnant women would be more motivated to stop smoking and, thus, 
have a better quit rate compared to non-pregnant women, but this was only found in a sub-analysis for 
young disadvantaged pregnant smokers. However, the women still smoking during pregnancy could be 
a more complex subgroup of all female smokers with special needs and challenges in relation to 
quitting. This complexity is supported by our findings with regard to the prognostic factors. On one 
hand, the pregnant women were characterised by positive prognostic factors, such as being enrolled in 
an individual programme format and lighter smoking in addition to the expected higher motivation 
caused by the pregnancy. On the other hand, they were also younger than 25 years old, were more 
often recommended to stop smoking by a health professional, had disadvantaged life conditions and 
were less often compliant with the programme, all factors related to a lower chance of continuous 
abstinence. One aspect that explains the similar effect of the GSP among pregnant and non-pregnant 
women is that these positive and negative factors balanced each other out in the pregnant group. 
However, other factors not included in the study, such as cultural factors, other lifestyle habits and 
firmer stress from midwifes and doctors to quit smoking, may be of greater importance. Other aspects 
that could explain this result are that the expected high motivation for quitting smoking during 
pregnancy may be overestimated and that the GSP could be relatively robust across socio-economic 
life conditions, as suggested in a previous study of disadvantaged smokers [18].  
Several important prognostic factors were identified in the present study, most of which have been 
previously described to be of similar importance [17–19]. In particular, the compliance with the GSP 
seemed superior to other factors. The successful continuous quit rate doubled for the participants that 
participated in two visits and doubled again for every subsequent visit, beginning at a few percentages 
after the first and ending at about thirty percent after participation in all five visits [17].  
Interestingly, young age seems to be an important prognostic factor with regard to quit rate; women 
younger than 25 years old were less likely to become smoke free compared to older women. In 
contrast, other studies of non-pregnant smokers have shown that young smokers are more successful in 
quitting compared to older smokers [28,29].  
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In spite of the great differences in national smoking prevalence according to age among pregnant 
smokers [13], our study shows that age per se does not have a significant effect on the continuous 
abstinence rate. From 1997–2005 the smoking prevalence for Danish pregnant women in the age group 
≤19 years old, actually increased from 37–43%, while it was relatively stable, approximately 27%, for 
the 20–24-year-olds [13]. In contrast, the smoking prevalence for pregnant women ≥25 years 
decreased from approximately 20% to less than 15%. 
Nicotine replacement therapy (NRT) is commonly used by the GSP. The recommendation of 
nicotine replacement therapy for pregnant women has been discussed for many years. Though it might 
be preferable to stop smoking without nicotine replacement therapy, it is most likely not realistic for 
the subgroup of pregnant smokers. Recent studies have determined a clear effect of nicotine 
replacement therapy in sufficient doses for pregnant women in both randomised clinical trials and 
studies on real life data [26,27]. In Denmark, it is recommended to consider NRT for pregnant women 
who continue to smoke at least 10 cigarettes daily after three months of pregnancy. The strength of the 
NRT should be selected according to the usual guidelines for non-pregnant women [30]. This may not 
be the case in other countries. In this study, 51% of the non-pregnant and 43% of the pregnant smokers 
used NRT to aid their quitting attempts. The more frequent use of NRT among non-pregnant smokers 
may be explained by a higher proportion of heavy smokers (see Table 1) as well as the more restrictive 
guidelines for the recommendation of NRT to pregnant smokers. 
This study has limitations as well as strengths. The follow-up rate was relatively high at 76%. The 
high number of pregnant as well as non-pregnant smokers was a strength of this study. Using 
continuous abstinence as the outcome measurement of smoking cessation intervention is recommended 
over point prevalence, as was performed in the present study [31]. The self-reported outcomes were a 
weakness of this study because patients may overestimate their abstinence rates approximately 3–6% 
[15,32–34]. Therefore, it is possible that pregnant women are more likely to overestimate their success, 
which could mean that non-pregnant women have a slightly higher quit rate compared to pregnant 
women. Furthermore, the generalisation of these results should be considered carefully because of 
different cultural traditions, smoking habits and socio-economic conditions, which should all be taken 
into account. Further implementation of the GSP in new areas should be followed up to determine if 
the expected results are obtained. 
New research should focus on comparing the GSP with other national, sub-regional or local 
smoking cessation intervention programs. It would be relevant to evaluate the smoking cessation rates 
among pregnant women that attended the GSP to that those that did not and to evaluate the smoking 
cessation rates of their smoking partners in a randomised design. Furthermore, it is necessary to 
measure the motivation level to quit smoking among pregnant smokers during their pregnancy 
compared to a non-pregnant control group. It is also necessary to deepen the qualitative interviews to 
better describe and understand the complexity, special needs and challenges of the pregnant smokers.  
Although smoking has been reduced in many countries, it is still a sizable problem [35] and 
continues to be a problem among pregnant women. From the literature, we know that between 0.5 and 
1% of smokers stop smoking every year in Denmark [16]. A Danish study that included all women that 
gave birth in 1997–2005, established that the average smoking prevalence among pregnant women 
decreased from 22% to 16% during that period of time [13], which corresponds to the national 
decrease in smoking prevalence. The GSP has a high clinical significance because smoking cessation 
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intervention can reduce the occurrence of low birth weight and preterm birth [33]. It is necessary to 
reach out to all pregnant women who are smokers, and smoking cessation intervention should be given 
the highest priority by policy makers and health care providers. The relatively high-effective GSP 
would be an attractive element of a future strategy targeting smoking cessation among all pregnant 
women.  
5. Conclusions 
Surprisingly, the Gold Standard programme seems to be as effective among the subgroup of 
smoking pregnant women as among non-pregnant smoking women. Only in the group of young 
disadvantaged smokers did the pregnant women show a significantly better continuous abstinence rate 
compared to the non-pregnant smokers. Successful quitting was associated with the individual 
intervention format, older age, higher compliance, not being a heavy smoker and not having 
disadvantaged life conditions. Due to its relatively high effect and clinical significance, the GSP would 
be an attractive element in future smoking cessation interventions among pregnant women.  
Acknowledgments 
Thanks to Kyle Raymond for his guidance, performance and interpretation of the statistical analyses 
and to Bolette Pedersen for her statistical and technical support. 
Conflicts of Interest 
The authors declare no conflicts of interest.  
References 
1. Lim, S.S.; Vos, T.; Flaxman, A.D.; Danaei, G.; Shibuya, K.; Adair-Rohani, H.; Amann, M.; 
Anderson, H.R.; Andrews, K.G.; Aryee, M.; et al. A comparative risk assessment of burden of 
disease and injury attributable to 67 risk factors and risk factor clusters in 21 regions, 1990–2010: 
A systematic analysis for the Global Burden of Disease Study 2010. Lancet 2013, 380, 2224–2260. 
2. Cnattingius, S. The epidemiology of smoking during pregnancy: Smoking prevalence, maternal 
characteristics, and pregnancy outcomes. Nicotine Tob. Res. 2004, 6 (Suppl 2), S125–S140. 
3. Schneider, S.; Huy, C.; Schütz, J.; Diehl, K. Smoking cessation during pregnancy: A systematic 
literature review. Drug Alcohol Rev. 2010, 29, 81–90. 
4. Wisborg, K.; Henriksen, T.B. Tobak og graviditet. Er der behov for forebyggelse? Findes der 
effektive metoder? (Tobacco and Pregnancy. Is There a Need for Prevention? Are There Effective 
Methods?); 1st ed.; The Danish Health and Medicines Authority: Copenhagen, Denmark, 2003. 
5. Wisborg, K.; Kesmodel, U.; Henriksen, T.B.; Olsen, S.F.; Secher, N.J. Exposure to tobacco 
smoke in utero and the risk of stillbirth and death in the first year of life. Am. J. Epidemiol. 2001, 
154, 322–327. 
6. McDonnell-Naughton, M.; McGarvey, C.; O’Regan, M.; Matthews, T. Maternal smoking and 
alcohol consumption during pregnancy as risk factors for sudden infant death. Irish Med. J. 2012, 
105, 105–108. 
Int. J. Environ. Res. Public Health 2013, 10 3665 
 
 
7. Wisborg, K.; Kesmodel, U.; Henriksen, T.B.; Olsen, S.F.; Secher, N.J. A prospective study of 
smoking during pregnancy and SIDS. Arch. Dis. Child. 2000, 83, 203–206. 
8. Wisborg, K.; Henriksen, T.B.; Obel, C.; Skajaa, E.; Ostergaard, J.R. Smoking during pregnancy 
and hospitalization of the child. Pediatrics 1999, 104, e46:1–e46:4. 
9. Andres, R.L.; Day, M.C. Perinatal complications associated with maternal tobacco use. Sem. 
Neonatol. 2000, 5, 231–241. 
10. Yang, Q.; Wen, S.W.; Phillips, K.; Oppenheimer, L.; Black, D.; Walker, M.C. Comparison of 
maternal risk factors between placental abruption and placenta previa. Am. J. Perinatol. 2009, 26, 
279–286. 
11. Benowitz, N.L.; Dempsey, D.A. Pharmacotherapy for smoking cessation during pregnancy. 
Nicotine Tob. Res. 2004, 6, 189–202. 
12. Shi, Y.; De Groh, M.; Morrison, H. Perinatal and early childhood factors for overweight and 
obesity in young Canadian children. Canad. J. Public Health 2013, 104, e69–e74. 
13. Egebjerg Jensen, K.; Jensen, A.; Nøhr, B.; Krüger Kjaer, S. Do pregnant women still smoke?  
A study of smoking patterns among 261,029 primiparous women in Denmark 1997–2005. Acta 
Obstetricia et Gynecologica Scandinavica 2008, 87, 760–767. 
14. Hiscock, R.; Judge, K.; Bauld, L. Social inequalities in quitting smoking: What factors mediate 
the relationship between socioeconomic position and smoking cessation? J. Public Health 2011, 
33, 39–47. 
15. Ferguson, J.; Bauld, L.; Chesterman, J.; Judge, K. The English smoking treatment services: One-
year outcomes. Addiction 2005, 100 (Suppl), 59–69. 
16. Rasmussen, M.; Ammari, A.B.H.; Pedersen, B.; Tønnesen, H. Smoking cessation intervention 
activities and outcome before, during and after the national Healthcare Reform in Denmark. Clin. 
Health Promot. 2012, 2, 26–35. 
17. Ghith, N.; Ammari, A.B.; Rasmussen, M.; Frølich, A.; Cooper, K.; Tønnesen, H. Impact of 
compliance on quit rates in a smoking cessation intervention: Population study in Denmark. Clin. 
Health Promot. 2012, 2, 111–119. 
18. Neumann, T.; Rasmussen, M.; Ghith, N.; Heitmann, B.L.; Tønnesen, H. The Gold Standard 
Programme: Smoking cessation interventions for disadvantaged smokers are effective in a real-
life setting. Tob. Contr. 2012, doi:10.1136/tobaccocontrol-2011-050194. 
19. Neumann, T.; Rasmussen, M.; Heitmann, B.L.; Tønnesen, H. Smoking cessation among heavy 
smokers in a real life setting. Int. J. Environ. Res. Public Health 2013, under review. 
20. Lind, M.; Jaspers, K. Manual til rygeafvænning i grupper (Manual for smoking cessation in 
groups); 2nd ed.; Danish Cancer Association: Copenhagen, Denmark, 2008. 
21. Lind, M.; Jaspers, K.; Kjaer, N.T. Rygeafvænning—Teori og praksis for professionelle rådgivere 
(Smoking Cessation—Theory and Practice of Professional Counsellors); 1st ed.; Danish Cancer 
Association: Copenhagen, Denmark, 2009. 
22. Lind, M.; Jaspers, K. Manual til individuel rygeafvænning (Manual for Individual Smoking 
Cessation); 5th ed.; Danish Cancer Association: Copenhagen, Denmark, 2011. 
23. Heatherton, T.F.; Kozlowski, L.T.; Frecker, R.C.; Fagerström, K.O. The Fagerström test for 
nicotine dependence: A revision of the Fagerström Tolerance Questionnaire. Br. J. Addict. 1991, 
86, 1119–1127. 
Int. J. Environ. Res. Public Health 2013, 10 3666 
 
 
24. Von Elm, E.; Altman, D.G.; Egger, M.; Pocock, S.J.; Gøtzsche, P.C.; Vandenbroucke, J.P. 
Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: 
Guidelines for reporting observational studies. BMJ 2007, 335, 806–808. 
25. West, R.; Hajek, P.; Stead, L.; Stapleton, J. Outcome criteria in smoking cessation trials: Proposal 
for a common standard. Addiction 2005, 100, 299–303. 
26. Myung, S.; Ju, W.; Jung, H.; Park, C.; Oh, S.; Seo, H.; Kim, H. Efficacy and safety of 
pharmacotherapy for smoking cessation among pregnant smokers: A meta-analysis. BJOG 2012, 
119, 1029–1039. 
27. Brose, L.S.; McEwen, A.; West, R. Association between nicotine replacement therapy use in 
pregnancy and smoking cessation. Drug Alcohol Depend. 2013, doi:10.1016/j.drugalcdep.201. 
28. Fidler, J.; Ferguson, S.G.; Brown, J.; Stapleton, J.; West, R. How does rate of smoking cessation 
vary by age, gender and social grade? Findings from a population survey in England. Addiction 
2013, doi:10.1111/add.12241. 
29. Messer, K.; Trinidad, D.R.; Al-Delaimy, W.K.; Pierce, J.P. Smoking cessation rates in the United 
States: A comparison of young adult and older smokers. Am. J. Public Health 2008, 98, 317–322. 
30. Medicinhåndbogen (The Medicine Handbook). Available online: http://pro.medicin.dk/ 
Laegemiddelgrupper/Grupper/315353#MASTER (accessed on 3 July 2013). 
31. Poulsen, P.B.; Dollerup, J.; Møller, A.M. Is a percentage a percentage? Systematic review of the 
effectiveness of Scandinavian behavioural modification smoking cessation programmes. Clin. 
Respir. J. 2010, 4, 3–12. 
32. Judge, K.; Bauld, L.; Chesterman, J.; Ferguson, J. The English smoking treatment services: Short-
term outcomes. Addiction 2005, 100 (Suppl), 46–58. 
33. Lumley, J.; Chamberlain, C.; Dowswell, T.; Oliver, S.; Oakley, L.; Watson, L. Interventions for 
promoting smoking cessation during pregnancy. Cochrane Database Syst. Rev. 2009, 
doi:10.1002/14651858.CD001055. 
34. Pisinger, C.; Vestbo, J.; Borch-Johnsen, K.; Thomsen, T.; Jørgensen, T. Acceptance of the 
smoking cessation intervention in a large population-based study: The Inter99 study. Scand. J. 
Public Health 2005, 33, 138–145. 
35. Lozano, R.; Naghavi, M.; Foreman, K.; Lim, S.; Shibuya, K.; Aboyans, V.; Abraham, J.; Adair, T.; 
Aggarwal, R.; Ahn, S.Y.; et al. Global and regional mortality from 235 causes of death for 20 age 
groups in 1990 and 2010: A systematic analysis for the Global Burden of Disease Study 2010. 
Lancet 2012, 380, 2095–2128.  
© 2013 by the authors; licensee MDPI, Basel, Switzerland. This article is an open access article 
distributed under the terms and conditions of the Creative Commons Attribution license 
(http://creativecommons.org/licenses/by/3.0/). 
